Biosimilar switching – current state of knowledge

Evidence from over 10 years of clinical experience demonstrates that biosimilar medicines approved in the European Union can be used for all their registered indications as safely as their originators and with no negative impact on therapeutic efficacy. The debate on the use of biosimilars in rheuma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Reumatologia
Autors principals: Wiland, Piotr, Batko, Bogdan, Brzosko, Marek, Kucharz, Eugeniusz J., Samborski, Włodzimierz, Świerkot, Jerzy, Więsik-Szewczyk, Ewa, Feldman, Julia
Format: Artigo
Idioma:Inglês
Publicat: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Matèries:
Review Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142020/
https://ncbi.nlm.nih.gov/pubmed/30237628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/reum.2018.77975
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars